|

Tremelimumab Clinical Trials

31 actively recruiting trials across 17 locations

▼ -2 trials since May 2026

Also known as: 745013-59-6, 745013-59-6, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP 675, CP 675206, CP-675, CP-675,206, CP-675206, CP675,, 745013-59-6, Anti-CTLA4 Human mAb (CP-675206/CP675), Imjudo, Immunoglobulin G2, Anti-(Human CTLA-4) mAb (Clone 11.2.1 heavy chain, disulfide), Anti-(Human CTLA-4 (Antigen)) (Human Monoclonal CP-675206 Clone 11.2.1 Heavy Chain) Disulfide with Human Monoclonal CP-675206 Clone 11.2.1 Light Chain, Anti-CTLA4 Human Monoclonal Antibody CP-675,206 +18 more

Pipeline

Early 1: 1Phase 1: 5Phase 2: 17Phase 3: 5Phase 1/2: 2Phase 2/3: 1

Top Sponsors

  • AstraZeneca3
  • The University of Hong Kong2
  • Chang Gung Memorial Hospital2
  • Anwaar Saeed2
  • Vall d'Hebron Institute of Oncology1

Indications

Other13 trials

A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab
Phase 1
A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
Phase 2
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
Phase 2
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
Phase 2
Durvalumab and Tremelimumab in Resectable HCC
Phase 2
Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis
Phase 2
Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma
Phase 2
Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
Phase 2
Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
Phase 2
Renal Adjuvant MultiPle Arm Randomised Trial
Phase 3
Single cEll pRofiling PErsistaNce To ImmuNothErapy
Phase 2
Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma
Phase 3
TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma
Phase 2

Phoenix, Arizona2 trials

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

BCG Oncology

Phase 1/2
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

Research Site

Phase 3

Goodyear, Arizona1 trial

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

CTCA at Western Regional Medical Center

Phase 2

Berkeley, California1 trial

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

Alta Bates Summit Medical Center-Herrick Campus

Phase 3

Duarte, California1 trial

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

City of Hope /ID# 261468

Phase 2/3

Los Angeles, California1 trial

SIRT With Tremelimumab and Durvalumab for Resectable HCC

Cedars-Sinai Medical Center

Phase 1

Orange, California1 trial

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

UC Irvine Health/Chao Family Comprehensive Cancer Center

Phase 2

San Diego, California1 trial

Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab

University of California, San Diego

Phase 1

San Francisco, California1 trial

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

University of California, San Francisco

Phase 2

Stanford, California1 trial

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Stanford University

Phase 3

Washington D.C., District of Columbia1 trial

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

Georgetown Lombardi Comprehensive Cancer Center

Phase 2

Jacksonville, Florida1 trial

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Mayo Clinic in Florida

Phase 1

Atlanta, Georgia1 trial

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

Grady Health System

Phase 2

Westwood, Kansas1 trial

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

University of Kansas Cancer Center

Phase 1/2

Baltimore, Maryland1 trial

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

SKCCC Johns Hopkins Medical Institution

Phase 1

Portland, Oregon1 trial

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

OHSU Knight Cancer Institute

Early 1

Pittsburgh, Pennsylvania1 trial

Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

UPMC Hillman Cancer Center

Phase 2

San Antonio, Texas1 trial

Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

UT Health San Antonio

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.